CompletedPhase 2/3

Nebulized Hypertonic Saline for Bronchiolitis

United States447 participantsStarted 2008-02

Plain-language summary

This study aims to examine the effect of nebulized 3% hypertonic saline in the treatment of viral bronchiolitis. The investigators hypothesize that nebulized 3% saline will decrease rate of hospital admission, decrease clinical severity scores, and decrease length of stay.

Who can participate

Age range24 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * clinical diagnosis of viral bronchiolitis * between November and April Exclusion Criteria: * prematurity \< 34 weeks * chronic lung disease * congenital heart disease * history of wheezing, asthma or albuterol use * tracheostomy status * need for intensive care of assisted ventilation

What they're measuring

Admission Rate

Timeframe: 1 day

Length of Stay

Timeframe: 1 month

Change in RDAI Score

Timeframe: 1 Hour

Trial details

NCT IDNCT00619918

SponsorChildren's Hospital Los Angeles

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-05

Results submitted2013-07-29

View on ClinicalTrials.gov More Bronchiolitis trials